Photo of Dominik Glodzik,  PhD

Dominik Glodzik, PhD

Harvard Medical School

Harvard Medical School


dominik_glodzik@hms.harvard.edu

Dominik Glodzik, PhD

Harvard Medical School

EDUCATIONAL TITLES

  • Instructor, Center for Biomedical Informatics at Countway, Harvard Medical School

HCC PROGRAM AFFILIATION

Research Abstract

Dominik's research at Harvard DBMI is focused on applications of statistical algorithms to understand, treat and detect cancer early.

During his postdoctoral fellowship at the Sanger Institute in the groups of Sir Prof Mike Stratton and Prof Serena Nik-Zainal he became an expert on detecting mutational patterns in cancer genomes. Specifically, he pioneered the use of supervised machine learning methods for the understanding of mutational processes in cancer. His most widely used algorithm is called HRDetect (Nature Medicine, Glodzik et al., 2017). This algorithm identifies cancer patients with homologous recombination deficiency (HRD) from genome sequencing data, widening the population of patients eligible for therapies. Because of his expertise in cancer genome analysis, he was recruited to the pediatric cancer program at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City, where he led an effort to build a cancer genome analysis platform. Together with the team, he successfully analyzed the MSKCC’s first 100 cancer patient genomes, discovering fusions which define both rare and hyper-mutated outlier pediatric cancers that may in future be candidates for rare patient cancer immunotherapies.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Herpers B, Eppink B, James MI, Cortina C, Cañellas-Socias A, Boj SF, Hernando-Momblona X, Glodzik D, Roovers RC, van de Wetering M, Bartelink-Clements C, Zondag-van der Zande V, Mateos JG, Yan K, Salinaro L, Basmeleh A, Fatrai S, Maussang D, Lammerts van Bueren JJ, Chicote I, Serna G, Cabellos L, Ramírez L, Nuciforo P, Salazar R, Santos C, Villanueva A, Stephan-Otto Attolini C, Sancho E, Palmer HG, Tabernero J, Stratton MR, de Kruif J, Logtenberg T, Clevers H, Price LS, Vries RGJ, Batlle E, Throsby M. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors. 2022; 3:418-436. PubMed
  • Glodzik D, Bosch A, Hartman J, Aine M, Vallon-Christersson J, Reuterswärd C, Karlsson A, Mitra S, Niméus E, Holm K, Häkkinen J, Hegardt C, Saal LH, Larsson C, Malmberg M, Rydén L, Ehinger A, Loman N, Kvist A, Ehrencrona H, Nik-Zainal S, Borg Å, Staaf J. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. Nat Commun 2020; 11:3747. PubMed
  • Staaf J, Glodzik D, Bosch A, Vallon-Christersson J, Reuterswärd C, Häkkinen J, Degasperi A, Amarante TD, Saal LH, Hegardt C, Stobart H, Ehinger A, Larsson C, Rydén L, Loman N, Malmberg M, Kvist A, Ehrencrona H, Davies HR, Borg Å, Nik-Zainal S. Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nat Med 2019; 25:1526-1533. PubMed
  • Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, Van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, Nik-Zainal S. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med 2017; 23:517-525. PubMed